Sugi Predict

Sugi Predict / Targets / CACNA1E

CACNA1E

Voltage-dependent R-type calcium channel subunit alpha-1E · Q15878 · CACNA1E on Sugi Atlas →

6,364 patent compounds predicted against CACNA1E, 2,663 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL6121858 SCHEMBL6121858 0.52 9/20
SCHEMBL2585915 SCHEMBL2585915 0.51 8/20
SCHEMBL3354274 SCHEMBL3354274 0.62 7/20
SCHEMBL3357851 SCHEMBL3357851 0.54 7/20
SCHEMBL4750473 SCHEMBL4750473 0.52 7/20
SCHEMBL3350921 SCHEMBL3350921 0.49 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL5428566 SCHEMBL5428566 0.52 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL4405461 SCHEMBL4405461 0.55 5/20
SCHEMBL4399845 SCHEMBL4399845 0.54 5/20
SCHEMBL4967687 SCHEMBL4967687 0.51 5/20
SCHEMBL1810921 SCHEMBL1810921 0.51 5/20
SCHEMBL4399843 SCHEMBL4399843 0.50 5/20
SCHEMBL3477582 SCHEMBL3477582 0.47 5/20
SCHEMBL3353571 SCHEMBL3353571 0.47 5/20

Clinical trials — most relevant to CACNA1E by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis PHASE2COMPLETED
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM) PHASE1COMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
International CRDS Registry nanRECRUITING
Verapamil in Supraclavicular Brachial Plexus Block nanUNKNOWN
High Density Mapping in Brugada Syndrome nanCOMPLETED
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia nanCOMPLETED
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
iCorMicA - Stratified Medicine in Angina nanRECRUITING
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy nanRECRUITING
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNA1E binder may also engage these)

ProteinNameSimilarity
P56698 — 1.000 P56698 →
Q61290 — 1.000 Q61290 →
Q02343 — 0.998 Q02343 →
O73700 — 0.997 O73700 →
Q07652 — 0.997 Q07652 →
Q05152 — 0.997 Q05152 →
P54282 — 0.997 P54282 →
CACNA1D Voltage-dependent L-type calcium channel subunit alpha-1D 0.997 landscape →
P97445 — 0.996 P97445 →
CACNA1A Voltage-dependent P/Q-type calcium channel subunit alpha-1A 0.996 landscape →
Q02294 — 0.993 Q02294 →
CACNA1B Voltage-dependent N-type calcium channel subunit alpha-1B 0.992 landscape →
P56699 — 0.992 P56699 →
P22002 — 0.991 P22002 →
P27884 — 0.991 P27884 →
P27732 — 0.991 P27732 →
O55017 — 0.991 O55017 →
KCNQ5 Potassium voltage-gated channel subfamily KQT member 5 0.989 landscape →
Q9NS40 — 0.989 Q9NS40 →
O54852 — 0.989 O54852 →
P02719 — 0.989 P02719 →
CACNA1I Voltage-dependent T-type calcium channel subunit alpha-1I 0.989 landscape →
Q62968 — 0.989 Q62968 →
Q9VW60 — 0.989 Q9VW60 →
P15381 — 0.989 P15381 →
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 0.989 landscape →
CACNA1C Voltage-dependent L-type calcium channel subunit alpha-1C 0.988 landscape →
P19334 — 0.988 P19334 →
CACNA1G Voltage-dependent T-type calcium channel subunit alpha-1G 0.988 landscape →
A2WYE9 — 0.988 A2WYE9 →